EPS growth in Q2 2010 GSK exercises option on Anacor’s novel antibiotic for the treatment of gram-negative infections
Jul 292010
Net sales up 2%; Medical Devices sales up 6% Diluted GAAP earnings per share from continuing operations were $0.70; excluding specified items, adjusted diluted earnings per share from continuing operations were $0.85, up 15% View PDF DUBLIN, Jul 29, 2010 (BUSINESS WIRE) -- Covidien plc (NYSE: COV) today reported results for the third quarter of fiscal 2010 (April - June 2010). Third-quarter net sales of $2.56 billion increased 2% from the $2.52 billion reported a year ago, with foreign exchange rate movement having no impact on the quarterly sales growth rate. Third-quarter 2010 gross margin of 55.6% rose 1.2 percentage points from the 54.4% of the prior-year period. This im...